Journal article · 2018 · Open access

F52. EFFICACY AND SAFETY OF LURASIDONE IN ADOLESCENTS WITH SCHIZOPHRENIA: INTERIM ANALYSIS OF A 24-MONTH, OPEN-LABEL EXTENSION STUDY

ROBERT S. GOLDMAN, Michael Tocco, Andrei Pikalov, Josephine B. Cucchiaro, Ling Deng, Antony D Loebel

Schizophrenia Bulletin, 44(suppl_1), S239 · Published 31 March 2018 · DOI 10.1093/schbul/sby017.583

Open full textCite this paper

In brief

“F52. EFFICACY AND SAFETY OF LURASIDONE IN ADOLESCENTS WITH SCHIZOPHRENIA: INTERIM ANALYSIS OF A 24-MONTH, OPEN-LABEL EXTENSION STUDY” is a 2018 journal article by ROBERT S. GOLDMAN and 5 co-authors, published in Schizophrenia Bulletin. OpenAlex counts 0 citations as of 20 November 2026. It is open access under a CC BY licence: the full text is free to read at Schizophrenia Bulletin.

Citations
0
Authors
6

Abstract

Long-term efficacy and safety data from prospective studies in adolescents with schizophrenia are limited. Lurasidone is an atypical antipsychotic that has demonstrated efficacy in the treatment of schizophrenia in both adults and adolescents. The aim of the current open-label trial was to obtain long-term data on the safety and effectiveness of lurasidone in adolescents with schizophrenia. Patients ages 13–17 with schizophrenia were randomized to 6 weeks of double-blind (DB) treatment with lurasidone 40 mg/d, 80 mg/d or placebo. Patients who completed this study were eligible to enroll in a 2-year, open-label (OL), flexible-dose (20–80 mg/d) extension study in which patients were continued on lurasidone, or switched from placebo to lurasidone. These data are the results of an interim analysis of the 2-year study. Effectiveness measures included the Positive and Negative Syndrome Scale (PANSS) total score (responder criteria, ≥20% reduction from double-blind baseline). A total of 271 patients completed 6 weeks of double-blind treatment and entered the 2-year extension study. At the time of the interim analysis, 132 patients had completed 52 weeks of treatment (24 patients were 2-year study completers; 96 patients were still ongoing; and 12 patients had discontinued after 52 weeks); 57 patients were still ongoing in the first 1-year of treatment; and 82 patients terminated prior to week 52 (28 patients due to withdrawal of consent; 23 due to adverse events; 9 due to lack of efficacy; and 22 for other reasons). Mean PANSS total score at double-blind baseline was 93.5. Overall mean change from double-blind to open-label baseline (after 6 weeks of treatment) was -17.5 (for patients assigned to lurasidone vs. placebo in the initial 6-week study, mean change was: -19.8 vs. -12.9). Overall mean change from double-blind baseline in the PANSS total score at weeks 28 (n=215), 52 (n=133), 76 (n=86), and 104 (n=24) was -29.2, -34.0, -35.0, and -34.1, respectively. Responder rates at week 52 and week 104 were 91.7% and 100%, respectively. During open-label treatment, the most common adverse events were headache (21.8%), nausea (11.8%), and anxiety (11.8%); 6.6% of patients reported an adverse event as severe. Median change in laboratory parameters from double-blind baseline to weeks 52 and 104, respectively, were: total cholesterol, -2.0 and -5.0 mg/dL; triglycerides, +3.5 and +3.0 mg/dL; hemoglobin A1c, 0.0 and 0.1%; prolactin in female, +0.5 and -0.5 ng/mL and males, +0.15 and +3.5 ng/mL; and mean change from DB baseline in weight at weeks 52 and 104 were 3.8 and 7.2 kg, vs. an expected weight gain of 3.3 and 5.1 kg, based on the gender-and-age…

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

GOLDMAN, R. S., Tocco, M., Pikalov, A., Cucchiaro, J. B., Deng, L., & Loebel, A. D. (2018). F52. EFFICACY AND SAFETY OF LURASIDONE IN ADOLESCENTS WITH SCHIZOPHRENIA: INTERIM ANALYSIS OF A 24-MONTH, OPEN-LABEL EXTENSION STUDY. Schizophrenia Bulletin, 44(suppl_1), S239. https://doi.org/10.1093/schbul/sby017.583

MLA 9

GOLDMAN, ROBERT S., et al. “F52. EFFICACY AND SAFETY OF LURASIDONE IN ADOLESCENTS WITH SCHIZOPHRENIA: INTERIM ANALYSIS OF A 24-MONTH, OPEN-LABEL EXTENSION STUDY.” Schizophrenia Bulletin, vol. 44, no. suppl_1, 2018, p. S239. https://doi.org/10.1093/schbul/sby017.583.

Chicago

GOLDMAN, ROBERT S., Michael Tocco, Andrei Pikalov, Josephine B. Cucchiaro, Ling Deng, and Antony D Loebel. 2018. “F52. EFFICACY AND SAFETY OF LURASIDONE IN ADOLESCENTS WITH SCHIZOPHRENIA: INTERIM ANALYSIS OF A 24-MONTH, OPEN-LABEL EXTENSION STUDY.” Schizophrenia Bulletin 44 (suppl_1): S239. https://doi.org/10.1093/schbul/sby017.583.

Harvard

GOLDMAN, R. S. et al. (2018) ‘F52. EFFICACY AND SAFETY OF LURASIDONE IN ADOLESCENTS WITH SCHIZOPHRENIA: INTERIM ANALYSIS OF A 24-MONTH, OPEN-LABEL EXTENSION STUDY’, Schizophrenia Bulletin, 44(suppl_1), p. S239. doi:10.1093/schbul/sby017.583.

IEEE

R. S. GOLDMAN, M. Tocco, A. Pikalov, J. B. Cucchiaro, L. Deng, and A. D. Loebel, “F52. EFFICACY AND SAFETY OF LURASIDONE IN ADOLESCENTS WITH SCHIZOPHRENIA: INTERIM ANALYSIS OF A 24-MONTH, OPEN-LABEL EXTENSION STUDY,” Schizophrenia Bulletin, vol. 44, no. suppl_1, p. S239, 2018, doi: 10.1093/schbul/sby017.583.

BibTeX

@article{goldman2018efficacy,
  title     = {{F52. EFFICACY AND SAFETY OF LURASIDONE IN ADOLESCENTS WITH SCHIZOPHRENIA: INTERIM ANALYSIS OF A 24-MONTH, OPEN-LABEL EXTENSION STUDY}},
  author    = {GOLDMAN, ROBERT S. and Tocco, Michael and Pikalov, Andrei and Cucchiaro, Josephine B. and Deng, Ling and Loebel, Antony D},
  journal   = {Schizophrenia Bulletin},
  year      = {2018},
  volume    = {44},
  number    = {suppl_1},
  pages     = {S239},
  doi       = {10.1093/schbul/sby017.583},
  url       = {https://doi.org/10.1093/schbul/sby017.583}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment

  • lurasidone
  • adolescent schizophrenia

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

GOLDMAN, R. S., Tocco, M., Pikalov, A., Cucchiaro, J. B., Deng, L., & Loebel, A. D. (2018). F52. EFFICACY AND SAFETY OF LURASIDONE IN ADOLESCENTS WITH SCHIZOPHRENIA: INTERIM ANALYSIS OF A 24-MONTH, OPEN-LABEL EXTENSION STUDY. Schizophrenia Bulletin, 44(suppl_1), S239. https://doi.org/10.1093/schbul/sby017.583

How many times has this paper been cited?

0 times, according to OpenAlex on 20 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Schizophrenia Bulletin: sign in and open the full text from this page.

Who wrote this paper?

ROBERT S. GOLDMAN, Michael Tocco, Andrei Pikalov, Josephine B. Cucchiaro, Ling Deng, Antony D Loebel.

What is the DOI of this paper?

10.1093/schbul/sby017.583, permanently at https://doi.org/10.1093/schbul/sby017.583. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 20 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.